{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:24Z","timestamp":1792787304778,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Varian Research Collaborations, Translational","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202929"],"award-info":[{"award-number":["82202929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Department of Science and Technology of Zhejiang Province","doi-asserted-by":"crossref","award":["2024C03161"],"award-info":[{"award-number":["2024C03161"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most colorectal cancers (CRCs) are mismatch repair-proficient (pMMR) and microsatellite stable (MSS), and they respond poorly to immune checkpoint inhibitors (ICIs). Radiotherapy (RT) can promote antitumor immunity but may also trigger adaptive immune suppression through checkpoint upregulation, providing a rationale for combination therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated transcriptomic analyses from The Cancer Genome Atlas and Gene Expression Omnibus cohorts\u2014annotated for microsatellite instability (MSI)\/MMR status\u2014with single-cell RNA-sequencing data from the Human Colorectal Cancer Atlas. Mechanistic and translational experiments were conducted using CT26 (MSS\/pMMR) and MC38 (microsatellite instability (MSI)-high\/mismatch repair-deficient (dMMR)) mouse models, patient-derived organoid (PDO)-immune co-cultures, and clinical CRC specimens. Assessments included multicolor flow cytometry, immunohistochemistry\/immunofluorescence, bulk RNA-sequencing, and immune profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>HAVCR2<\/jats:italic>\n                      (T cell immunoglobulin and mucin-domain containing-3 (TIM-3)) and\n                      <jats:italic>LGALS9<\/jats:italic>\n                      (galectin-9) were broadly expressed in CRC, remaining relatively high in MSS\/pMMR tumors compared with most other checkpoints. In CT26 tumors, RT preferentially increased programmed cell death protein 1 (PD-1) and TIM-3 co-expression on intratumoral CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and natural killer (NK) cells, whereas these changes were weaker and less consistent in MC38 tumors. The addition of TIM-3 blockade to RT plus programmed death-ligand 1 (PD-L1) blockade produced the most durable antitumor activity in CT26 tumors, improving primary tumor control, abscopal effects, and protection against tumor rechallenge. In PDO-immune co-cultures, pMMR PDOs showed a consistent incremental benefit when TIM-3 blockade was added to RT+PD-L1 blockade, whereas this added benefit was less consistent in dMMR PDOs. In clinical datasets and specimens, RT-containing treatment was associated with increased T-cell infiltration and higher TIM-3\/PD-1 signals; stereotactic body radiotherapy was accompanied by systemic immune alterations, including TIM-3 induction on circulating immune subsets. Across pan-cancer cohorts treated with ICIs, concomitantly high expression of\n                      <jats:italic>HAVCR2<\/jats:italic>\n                      and\n                      <jats:italic>PDCD1<\/jats:italic>\n                      correlated with an immune-activated transcriptional profile and improved clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings identify TIM-3\/PD-L1 as a context-dependent adaptive resistance axis following RT. The greatest incremental value of TIM-3 blockade was observed in MSS\/pMMR settings, where RT more consistently increased PD-1 and TIM-3 co-expression on intratumoral CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and NK cells. Combining RT with dual TIM-3\/PD-L1 blockade warrants further clinical evaluation for immunotherapy-refractory CRC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013656","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:10:15Z","timestamp":1771949415000},"page":"e013656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer"],"prefix":"10.1136","volume":"14","author":[{"given":"Xuan Xuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Orthopedics Research Institute, Zhejiang University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-8517","authenticated-orcid":false,"given":"Sheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-4191","authenticated-orcid":false,"given":"Xiaonan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026022408101059000_14.2.e013656.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32319-0"},{"key":"2026022408101059000_14.2.e013656.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21772"},{"key":"2026022408101059000_14.2.e013656.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"2026022408101059000_14.2.e013656.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.09.008"},{"key":"2026022408101059000_14.2.e013656.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2026022408101059000_14.2.e013656.6","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030618","article-title":"Immunotherapy, Inflammation and Colorectal Cancer","volume":"9","author":"Lichtenstern","year":"2020","journal-title":"Cells"},{"key":"2026022408101059000_14.2.e013656.7","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12520"},{"key":"2026022408101059000_14.2.e013656.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026022408101059000_14.2.e013656.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6"},{"key":"2026022408101059000_14.2.e013656.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00552-7"},{"key":"2026022408101059000_14.2.e013656.11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643"},{"key":"2026022408101059000_14.2.e013656.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637"},{"key":"2026022408101059000_14.2.e013656.13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2026022408101059000_14.2.e013656.14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026022408101059000_14.2.e013656.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0096"},{"key":"2026022408101059000_14.2.e013656.16","doi-asserted-by":"crossref","unstructured":"Rapoport BL , Anderson R . Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. Int J Mol Sci 2019;20. doi:10.3390\/ijms20040959","DOI":"10.3390\/ijms20040959"},{"key":"2026022408101059000_14.2.e013656.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.09.018"},{"key":"2026022408101059000_14.2.e013656.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.06.001"},{"key":"2026022408101059000_14.2.e013656.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"2026022408101059000_14.2.e013656.20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2026022408101059000_14.2.e013656.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1535"},{"key":"2026022408101059000_14.2.e013656.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1038"},{"key":"2026022408101059000_14.2.e013656.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.014"},{"key":"2026022408101059000_14.2.e013656.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00149-2"},{"key":"2026022408101059000_14.2.e013656.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.009"},{"key":"2026022408101059000_14.2.e013656.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-019-0232-9"},{"key":"2026022408101059000_14.2.e013656.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8"},{"key":"2026022408101059000_14.2.e013656.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01079-6"},{"key":"2026022408101059000_14.2.e013656.29","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-15-190","article-title":"Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma","volume":"15","author":"Castle","year":"2014","journal-title":"BMC Genomics"},{"key":"2026022408101059000_14.2.e013656.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02424-0","article-title":"Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution","volume":"9","author":"Efremova","year":"2018","journal-title":"Nat Commun"},{"key":"2026022408101059000_14.2.e013656.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.049"},{"key":"2026022408101059000_14.2.e013656.32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2026022408101059000_14.2.e013656.33","article-title":"Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer","volume":"51","author":"Bae","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026022408101059000_14.2.e013656.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.10.006"},{"key":"2026022408101059000_14.2.e013656.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.09.013"},{"key":"2026022408101059000_14.2.e013656.36","doi-asserted-by":"publisher","DOI":"10.1097\/01.shk.0000142249.08135.e9"},{"key":"2026022408101059000_14.2.e013656.37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17233849","article-title":"Radiation-Induced Immune Responses from the Tumor Microenvironment to Systemic Immunity","volume":"17","author":"Png","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026022408101059000_14.2.e013656.38","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12074"},{"key":"2026022408101059000_14.2.e013656.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101480"},{"key":"2026022408101059000_14.2.e013656.40","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-022-02153-9","article-title":"Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy","volume":"17","author":"R\u00fchle","year":"2022","journal-title":"Radiat Oncol"},{"key":"2026022408101059000_14.2.e013656.41","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.7150\/jca.31755","article-title":"Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer","volume":"10","author":"Yu","year":"2019","journal-title":"J Cancer"},{"key":"2026022408101059000_14.2.e013656.42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4149\/neo_2021_201210N1341","article-title":"Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer","volume":"68","author":"Peng","year":"2021","journal-title":"Neoplasma"},{"key":"2026022408101059000_14.2.e013656.43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250432"},{"key":"2026022408101059000_14.2.e013656.44","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"2026022408101059000_14.2.e013656.45","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2026022408101059000_14.2.e013656.46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41419-023-05806-z","article-title":"Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer","volume":"14","author":"K\u00e4llberg","year":"2023","journal-title":"Cell Death Dis"},{"key":"2026022408101059000_14.2.e013656.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0238-9"},{"key":"2026022408101059000_14.2.e013656.48","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability\u2013High Locally Advanced Rectal Cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026022408101059000_14.2.e013656.49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026022408101059000_14.2.e013656.50","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:10:22Z","timestamp":1771949422000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013656"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013656","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}